Transcription activity is required for p53-dependent tumor suppression

Oncogene

Volumn 28, Issue 49, 2009, Pages 4397-4401

  Gaidarenko, O ^a   Xu, Y ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Metastasis; P53; Transcription activity; Tumor suppression

Indexed keywords

CRE RECOMBINASE; PROTEIN P53; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; DNA DAMAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMOCYTE; THYMUS LYMPHOMA; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; MICE; MICE, TRANSGENIC; MUTANT PROTEINS; NEOPLASM METASTASIS; THYMOMA; THYMUS GLAND; THYMUS NEOPLASMS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

MUS; MUS MUSCULUS;

EID: 72049095062     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.290     Document Type: Article

References (28)

1. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. (1995). Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557.
2. Chao C, Hergenhahn M, Kaeser MD, Wu Z, Saito S, Iggo R et al. (2003). Cell type-and promoter-specific roles of Ser18 phospho-rylation in regulating p53 responses. J Biol Chem 278: 41028-41033.
3. Chao C, Herr D, Chun J, Xu Y. (2006a). Ser18 and 23 phosphoryla-tion is required for p53-dependent apoptosis and tumor suppression. EMBO J 25: 2615-2622.
4. Chao C, Saito S, Kang J, Anderson CW, Appella E, Xu Y. (2000). p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J 19: 4967-4975.
5. Chao C, Wu Z, Mazur SJ, Borges H, Rossi M, Lin T et al. (2006b). Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol 26: 6859-6869.
6. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M et al. (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303: 1010-1014.
7. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. (1995). Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
8. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS et al. (1992). Mice deficient for p53 are developmen-tally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
9. Inlay M, Alt FW, Baltimore D, Xu Y. (2002). Essential roles of the [kappa] light chain intronic enhancer and 3[prime] enhancer in [kappa] rearrangement and demethylation. Nat Immunol 3: 463-468.
10. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
11. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J et al. (2003). Puma is an essential mediator of p53-dependent and-independent apoptotic pathways. Cancer Cell 4: 321-328.
12. Johnson TM, Hammond EM, Giaccia A, Attardi LD. (2005). The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat Genet 37: 145-152.
13. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. (2001). Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418-425.
14. Ko LJ, Prives C. (1996). p53: puzzle and paradigm. Genes Dev 10: 1054-1072.
15. Kortlever RM, Higgins PJ, Bernards R. (2006). Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 8: 877-884.
16. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
17. Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S, Makar KW et al. (2001). A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15: 763-774.
18. Lin J, Chen J, Elenbaas B, Levine AJ. (1994). Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8: 1235-1246.
19. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E et al. (2005). p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 7: 165-171.
20. Michael D, Oren M. (2002). The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 12: 53-59.
21. Moll UM, Wolff S, Speidel D, Deppert W. (2005). Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 17: 631-636.
22. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
23. Oren M. (2003). Decision making by p53: life, death and cancer. Cell Death Differ 10: 431-442.
24. Schuler M, Green DR. (2005). Transcription, apoptosis and p53: catch-22. Trends Genet 21: 182-187.
25. Song H, Hollstein M, Xu Y. (2007). p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9: 573-580.
26. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ et al. (2003). p53-and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036-1038.
27. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T et al. (2006). A global map of p53 transcription-factor binding sites in the human genome. Cell 124: 207-219.
28. Xu Y. (2005). A new role for p53 in maintaining genetic stability in embryonic stem cells. Cell Cycle 4: 363-364.